Expression of MACC1 and MET in inflammatory bowel disease-associated colonic neoplasia

Inflammatory Bowel Diseases

Volumn 20, Issue 4, 2014, Pages 703-711

  Harpaz, Noam ^a   Taboada, Sofia ^b   Ko, Huaibin Mabel ^a   Yu, Jiangzhou ^b   Yang, Qi ^b   Xu, Haodong ^c   Cao, Wenqing ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Colorectal adenocarcinoma; Dysplasia; Inflammatory bowel disease; MET; Metastasis associated in colon cancer 1

Indexed keywords

SCATTER FACTOR RECEPTOR; MACC1 PROTEIN, HUMAN; MET PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADULT; ARTICLE; CANCER PROGNOSIS; CARCINOGENESIS; CELL DIFFERENTIATION; CLINICAL FEATURE; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL DYSPLASIA; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BOWEL DISEASE; MACC1 GENE; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; SIGNET RING CARCINOMA; TISSUE MICROARRAY; TUMOR DIFFERENTIATION; ADENOCARCINOMA; AGED; CANCER GRADING; CHEMISTRY; COLLOID CARCINOMA; COLON; COLORECTAL TUMOR; CROHN DISEASE; METABOLISM; MIDDLE AGED; PATHOLOGY; ULCERATIVE COLITIS; YOUNG ADULT;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; CARCINOMA, SIGNET RING CELL; COLITIS, ULCERATIVE; COLON; COLORECTAL NEOPLASMS; CROHN DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROTO-ONCOGENE PROTEINS C-MET; TRANSCRIPTION FACTORS; YOUNG ADULT;

EID: 84898742354     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000442679.39804.48     Document Type: Article

References (43)

1. Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18(suppl 2):1-5.
2. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526-535.
3. Jess T, Gamborg M, Matzen P, et al. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol. 2005;100:2724-2729.
4. Feagins LA, Souza RF, Spechler SJ. Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol. 2009;6:297-305.
5. Westbrook AM, Szakmary A, Schiestl RH. Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models. Mutat Res. 2010;705:40-59.
6. Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther. 2006;23:1097-1104.
7. Grivennikov SI. Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol. 2013;35:229-244.
8. Stein U, Walther W, Arlt F, et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med. 2009;15:59-67.
9. Stein U, Smith J, Walther W, et al. MACC1 controls Met: what a difference an Sp1 site makes. Cell Cycle. 2009;8:2467-2469.
10. Arlt F, Stein U. Colon cancer metastasis: MACC1 and Met as metastatic pacemakers. Int J Biochem Cell Biol. 2009;41:2356-2359.
11. Shirahata A, Shinmura K, Kitamura Y, et al. MACC1 as a marker for advanced colorectal carcinoma. Anticancer Res. 2010;30:2689-2692.
12. Ren B, Zakharov V, Yang Q, et al. MACC1 is related to colorectal cancer initiation and early-stage invasive growth. Am J Clin Pathol. 2013;140: 701-707.
13. Zeng Z, Weiser MR, D'Alessio M, et al. Immunoblot analysis of c-Met expression in human colorectal cancer: overexpression is associated with advanced stage cancer. Clin Exp Metastasis. 2004;21:409-417.
14. Zeng ZS, Weiser MR, Kuntz E, et al. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett. 2008;265:258-269.
15. Fujita S, Sugano K. Expression of c-met proto-oncogene in primary colorectal cancer and liver metastases. Jpn J Clin Oncol. 1997;27:378-383.
16. De Oliveira AT, Matos D, Logullo AF, et al. MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality. Anticancer Res. 2009;29:4807-4811.
17. Ording AG, Horvath-Puho E, Erichsen R, et al. Five-year mortality in colorectal cancer patients with ulcerative colitis or Crohn's disease: a nationwide population-based cohort study. Inflamm Bowel Dis. 2013; 19:800-805.
18. Redston M. Epithelial neoplasms of the large intestine. In: Goldblum JR, Odze RD, eds. Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas. 2nd ed. Philadelphia, PA: Saunders; 2009:597-637.
19. Hyngstrom JR, Hu CY, Xing Y, et al. Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base. Ann Surg Oncol. 2012;19:2814-2821.
20. Zakharov V, Ren B, Ryan C, et al. Diagnostic value of HMGAs, p53 and beta-catenin in discriminating adenocarcinoma from adenoma or reactive atypia in ampulla and common bile duct biopsies. Histopathology. 2013; 62:778-787.
21. Baars JE, Kuipers EJ, van Haastert M, et al. Age at diagnosis of inflammatory bowel disease influences early development of colorectal cancer in inflammatory bowel disease patients: a nationwide, long-term survey. J Gastroenterol. 2012;47:1308-1322.
22. Psathakis D, Schiedeck TH, Krug F, et al. Ordinary colorectal adenocarcinoma vs. primary colorectal signet-ring cell carcinoma: study matched for age, gender, grade, and stage. Dis Colon Rectum. 1999;42:1618-1625.
23. Shimokawa H, Uramoto H, Onitsuka T, et al. Overexpression of MACC1 mRNA in lung adenocarcinoma is associated with postoperative recurrence. J Thorac Cardiovasc Surg. 2011;141:895-898.
24. Wang G, Kang MX, Lu WJ, et al. MACC1: a potential molecule associated with pancreatic cancer metastasis and chemoresistance. Oncol Lett. 2012;4:783-791.
25. Meng F, Li H, Shi H, et al. MACC1 down-regulation inhibits proliferation and tumourigenicity of nasopharyngeal carcinoma cells through Akt/betacatenin signaling pathway. PloS One. 2013;8:e60821.
26. Zhang Y, Wang Z, Chen M, et al. MicroRNA-143 targets MACC1 to inhibit cell invasion and migration in colorectal cancer. Mol Cancer. 2012;11:23.
27. Redston MS, Papadopoulos N, Caldas C, et al. Common occurrence of APC and K-ras gene mutations in the spectrum of colitis-associated neoplasias. Gastroenterology. 1995;108:383-392.
28. Tarmin L, Yin J, Harpaz N, et al. Adenomatous polyposis coli gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms. Cancer Res. 1995;55:2035-2038.
29. Aust DE, Terdiman JP, Willenbucher RF, et al. The APC/beta-catenin pathway in ulcerative colitis-related colorectal carcinomas: a mutational analysis. Cancer. 2002;94:1421-1427.
30. Baldus SE, Kort EJ, Schirmacher P, et al. Quantification of MET and hepatocyte growth factor/scatter factor expression in colorectal adenomas, carcinomas and non-neoplastic epithelia by quantitative laser scanning microscopy. Int J Oncol. 2007;31:199-204.
31. Gao J, Ding F, Liu Q, et al. Knockdown of MACC1 expression suppressed hepatocellular carcinoma cell migration and invasion and inhibited expression of MMP2 and MMP9. Mol Cell Biochem. 2013;376:21-32.
32. Soderlund S, Granath F, Brostrom O, et al. Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. Gastroenterology. 2010;138:1697-1703.
33. Basseri RJ, Basseri B, Papadakis KA. Dysplasia and cancer in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2011;5:59-66.
34. Brackmann S, Andersen SN, Aamodt G, et al. Two distinct groups of colorectal cancer in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:9-16.
35. Svrcek M, Cosnes J, Beaugerie L, et al. Colorectal neoplasia in Crohn's colitis: a retrospective comparative study with ulcerative colitis. Histopathology. 2007;50:574-583.
36. Connell WR, Sheffield JP, Kamm MA, et al. Lower gastrointestinal malignancy in Crohn's disease. Gut. 1994;35:347-352.
37. Hamilton SR. Colorectal carcinoma in patients with Crohn's disease. Gastroenterology. 1985;89:398-407.
38. Ogino S, Brahmandam M, Cantor M, et al. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol. 2006;19:59-68.
39. Park ET, Oh HK, Gum JR Jr, et al. HATH1 expression in mucinous cancers of the colorectum and related lesions. Clin Cancer Res. 2006; 12:5403-5410.
40. Park ET, Gum JR, Kakar S, et al. Aberrant expression of SOX2 upregulates MUC5AC gastric foveolar mucin in mucinous cancers of the colorectum and related lesions. Int J Cancer. 2008;122:1253-1260.
41. Ogino S, Odze RD, Kawasaki T, et al. Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma. Am J Surg Pathol. 2006; 30:1175-1183.
42. Kim HS, Kang SH, Park CH, et al. Genome-wide molecular characterization of mucinous colorectal adenocarcinoma using cDNA microarray analysis. Oncol Rep. 2011;25:717-727.
43. Brackmann S, Andersen SN, Aamodt G, et al. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease. Scand J Gastroenterol. 2009;44:46-55.